28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Among 5757 participants (21.7% Black, 20.3% Latinx, 58.1% AORE), we found lower odds of amyloid positivity in Black (odds ratio [OR]: 0.72, 95% confidence interval [CI]: 0.62-0.83) and Latinx (OR: 0.78, 95% CI: 0.67-0.91) compared to AORE. 4 key findings →
Participants: 5,757 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Plasma p-tau217-based biomarkers showed excellent detecting performance for early amyloid (Thal I-II; area under the curve values > 0.96) and intermediate tau (Braak III-IV; area under the curve values > 0.92). 5 key findings →
Participants: 237 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of the 944 clinical cases, 13.0% were characterized as probable LATE (2.4% pure LATE and 10.6% LATE+AD) and 23.7% were characterized as probable AD without LATE. 5 key findings →
Participants: 944 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Additionally, growing evidence suggests that neuroinflammation may modulate the effects of tau spread on cognitive impairment in AD [Peretti, Débora E., et al., Brain 147.12 (2024): 4094‐4104.]. 5 key findings →
Design: longitudinal study Participants: 354 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
CSF Aβ42/Aβ40 contributed most to identify Aβ-positivity, while continuous Aβ-PET load within the positive range was best predicted by plasma P-tau217. 1 key finding →
Participants: 1,053 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We analyzed data from 1,542 participants (mean age = 72.2 years, SD = 7.2; 50.8% female; mean education = 16.3 years, SD = 2.6) and found that APOE4 was associated with steeper declines in episodic memory as a function of Aβ duration. 5 key findings →
Participants: 1,542 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The mean (SD) age of participants was 70.57 (8.00) years, with 179 (42.9 %) females. 5 key findings →
Design: cross-sectional Participants: 123 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
EXT showed high cross-sectional reliability and longitudinal stability. 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Four cognitive phenotypes emerged. One phenotype (18% of Aβ+ participants) showed the steepest cognitive decline, highest progression on the CDR, greater baseline medial temporal tau, and fastest neocortical tau accumulation over 4.6 years (hazard ratio [HR] for decline ≈ 2.9). 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Bringing together global efforts to enhance the implementation of warnings in managing vulnerabilities, hazards, risks, and disasters is essential to saving lives and for long-term vulnerability reduction. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Pancreatic cancer (PC), particularly pancreatic ductal adenocarcinoma (PDAC), is a significant global health issue with high mortality rates. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Nature-based Solutions (NbS) are increasingly recognized as effective measures for mitigating flood risks and enhancing climate change adaptation. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Key Points Disasters cause significant human suffering, and patients with kidney diseases are uniquely vulnerable. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
An international expert panel convened to evaluate nutrition-based approaches to brain health and dementia prevention. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Oral diseases have emerged as one of the most prevalent non-communicable diseases (NCDs) worldwide, with a high global average prevalence of 45%, affecting an estimated 3.5 billion people globally. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Vascular dementia (VaD) is the second leading cause of dementia after Alzheimer's disease (AD). 1 key finding →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Lifestyle factors and ambient air pollution are linked to dementia and CMDs, yet few studies have investigated their impact on dementia risk in CMDs patients at the same time. 1 key finding →
Participants: 438,681 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Science can help to target climate finance at better-quality adaptation. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The findings indicate that stronger ESG practices significantly reduce corporate risk, enhance financial stability, and mitigate regulatory and market volatility exposure. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Dementia is a leading health policy challenge, with cases expected to triple by 2050, particularly in low- and middle-income countries. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Excessive intake of dietary fats is strongly associated with an increased risk of various chronic diseases, such as obesity, diabetes, hepatic metabolic disorders, cardiovascular disease, chronic intestinal inflammation, and certain cancers. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Recommendations for HCAP adaptation include phases of preparation (assembling local expert teams; resource planning), implementation (construct-centered adaptation guided by local experts), pre-testing (iterative, mixed-methods approach), and field preparation (creating documentation; interviewer training; planning for ongoing quality assurance). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our findings suggest that disease progression follows a stage-dependent MVD pattern that can identify at-risk regions. 5 key findings →
Participants: 403 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We used cross-sectional data from the NHANES (National Health and Nutrition Examination Survey) from 1999 to 2018 linked to National Death Index records. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Diagnostic challenges stem from overlapping symptoms of co-occurring neurodevelopmental and psychiatric conditions, rendering standard dementia tools insufficient. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →